Aspect Biosystems develops bioprinted tissue therapeutics to treat serious metabolic and endocrine diseases using AI-powered bioprinting technology.

Eikonizo Therapeutics is a biotechnology company developing disease-modifying therapies for neurodegenerative and cardiorenal diseases, focusing on a novel HDAC6 inhibitor.